1-3 of 3
Authors: Jeffrey Ravetch
Journal Article
CTIM-13. D2C7-IT IN COMBINATION WITH AN FC-ENGINEERED ANTI-HUMANCD40 MONOCLONAL ANTIBODY (2141-V11) ADMINISTERED INTRATUMORALLY VIA CONVECTION-ENHANCED DELIVERY (CED) FOLLOWED BY CERVICAL PERILYMPHATIC INJECTIONS (CPLIS) OF 2141-V11 IN PATIENTS WITH RECURRENT GLIOBLASTOMA (RGBM) Purchased
Neuro-Oncology, Volume 26, Issue Supplement_8, November 2024, Page viii87, https://doi.org/10.1093/neuonc/noae165.0346
Published: 11 November 2024
Journal Article
CTIM-09. PHASE 1/1B TRIAL OF FC-ENGINEERED ANTI-CD40 AGONIST MONOCLONAL ANTIBODY (2141-V11) INFUSED WITH D2C7-IT IN ENHANCING DISEASE BY CONVECTION-ENHANCED DELIVERY (CED) FOR RECURRENT MALIGNANT GLIOMA (RMG) Purchased
Neuro-Oncology, Volume 25, Issue Supplement_5, November 2023, Pages v62–v63, https://doi.org/10.1093/neuonc/noad179.0249
Published: 10 November 2023
Journal Article
CTIM-23. DOSE ESCALATION TRIAL OF FC-ENGINEERED ANTI-CD40 MONOCLONAL ANTIBODY (2141-V11) ADMINISTERED INTRATUMORALLY WITH D2C7-IT VIA CONVECTION-ENHANCED DELIVERY (CED) FOR RECURRENT MALIGNANT GLIOMAS (RMGS) Purchased
Neuro-Oncology, Volume 24, Issue Supplement_7, November 2022, Page vii65, https://doi.org/10.1093/neuonc/noac209.255
Published: 14 November 2022
